Popular Articles

Michigan Legislature Considering Insurance Reform Bills
"There"s support in Michigan"s Legislature for eliminating insurance practices that deny coverage and charge high rates for people with chronic health problems. But the Michigan reforms face a tight timetable as lawmakers focus on the state"s worsening budget crisis," The Detroit Free Press reports. One Republican plan in the state Senate would address the problem of lost coverage from rising unemployment in Michigan by requiring "businesses -- including self-insured enterprises such as General Motors Corp. and Chrysler Group LLC, now exempt from state regulations, -- to pay to expand health care for poor people. The Detroit Regional Chamber and others oppose new taxes in the Senate plan, particularly when so many businesses are hurting" (Anstett, 7/6).
new payday loan lenders
Buy zoloft and forget about depression.
Boehringer Ingelheim And Vitae Pharmaceuticals Announce A Major Collaboration To Research And Develop Novel Treatments For Alzheimer`s Disease
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer"s disease. Current therapies for Alzheimer"s disease can improve symptoms, but do not affect the progression of the disease. The inhibition of BACE - an enzyme involved in the formation of amyloid-beta plaques which accumulate in the brains of patients with Alzheimer"s disease - offers the potential to slow or even halt disease progression.
News of the day
The Therapeutic Process Of Mother-Infant Psychotherapy
Psychotherapists who treat mothers suffering from postpartum depression and other mood disorders with their infants have developed a proven process that contributes to a greater positive experience with immediate insights for the mothers to develop healthy connections between their maternal experiences and their infants" behaviors.
Oncology

Kai Sensors Receives FDA Clearance For Its Wireless, Non-Contact Respiratory Device

Hawaii-based Kai Sensors announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Kai Sensors Non-Contact Respiratory Rate Spot Check, also called the Kai RSpot. The 510(k) clearance allows Kai Sensors to market the Kai RSpot to physicians, hospitals, and clinics. The Kai RSpot is a device that offers a practical and effective approach of measuring respiratory rate in hospital and clinical settings. The device is easy to use and works wirelessly, with no contact or attachment to the patient. Due to difficulties with current approaches of measuring respiratory rate, this important vital sign is often measured infrequently, inaccurately, inconsistently, or not at all. The clinically tested Kai RSpot provides a solution that addresses many of the shortcomings of existing technologies, and will enable doctors and health care professionals to measure a patient"s respiration with greater ease and with increased regularity. "The 510(k) approval from the FDA is a major milestone for Kai Sensors that will enable our Company to continue to grow," said Kai Sensors CEO Andrea Yuen. "We believe the Kai RSpot will make collecting respiratory information easier for physicians and clinicians and thus help increase the amount of information available about a patient and improve the overall quality of health care." Kai Sensors, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):